After a challenging year in the wake of the FDA decision on MDMA-assisted therapy for PTSD, the MAPS Board of Directors has embraced a new model of leadership, naming Betty Aldworth and Ismail Lourido Ali as co-executive directors. The post MAPS Moves Forward With New Leadership Model first appeared on Lucid News. The post MAPS Moves Forward With New Leadership Model appeared first on Lucid News.| Lucid News
San Jose, CA; September 4, 2025 — In August 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Lykos Therapeutics, declining to approve MDMA-assisted therapy for Posttraumatic Stress Disorder (PTSD). Today, the FDA made this CRL publicly available for the first time, providing transparency into the agency’s decision-making process. … Continue reading MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy| Multidisciplinary Association for Psychedelic Studies – MAPS